Effectiveness and safety of switching to adalimumab biosimilar ABP 501 in Crohn's disease: the extrapolation concept.

Davide Giuseppe RibaldoneMarta VerneroMarco Astegiano

Published in: Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva (2021)

We sincerely thank Viscido et al. for their appropriate and sharable comments on our recent study on adalimumab biosimilar ABP 501 in Crohn's disease (CD). The use of a biosimilar in inflammatory disorders is one of the current main topics, given the great opportunity to save resources that can be invested in innovative drugs and the ethical problems that non-medical switching can generate.

Keyphrases

rheumatoid arthritis
juvenile idiopathic arthritis
mental health
oxidative stress
ulcerative colitis
hidradenitis suppurativa
decision making